The pharmaceutical patent system was designed for a different drug. A small molecule, synthesized in a lab, dosed the same […]
Drug Patents Are Breaking: How Personalized Medicine Is Exposing the Cracks Read Post »
Quick Summary: Traditional pharmaceutical market research tells you what happened yesterday. A patent analyst suite tells you what will happen
A competitor’s pipeline is not a secret. It is a public record, filed in tranches at the USPTO, EPO, and
Reverse Engineer a Competitor’s Drug Pipeline Using Patent Filings Read Post »
GW Pharmaceuticals spent roughly two decades and hundreds of millions of dollars turning cannabis extracts into regulated pharmaceuticals. When Jazz
The pharmaceutical industry spent the last decade automating drug discovery. Billions went into generative chemistry platforms, phenomic screening systems, and
Who Owns the AI-Discovered Drug? The Pharmaceutical Patent Ownership Crisis Explained Read Post »
The standard Paragraph IV playbook was written for atorvastatin and metformin, not for drugs prescribed to 800 patients nationwide. When
Rare Disease Patents: Why Challengers Need a Different Playbook Read Post »
The pharmaceutical vendor ecosystem — CROs, CDMOs, biomarker platform providers, data analytics firms, and laboratory services companies — has spent
Diagnostic Patents: The IP Frontier That Pharma Vendors Can No Longer Ignore Read Post »
The FDA’s Purple Book is supposed to be the authoritative public registry for biologic drug patents in the United States.
Biologic Patent Tracking: What to Do When the Purple Book Fails You Read Post »
How combination patent architecture protects pharmaceutical revenue after composition-of-matter expiry — and what the post-Teva v. Amneal landscape means for
Your Drug Needs a Device Patent to Survive: The MedTech Crossover Strategy Read Post »
Sign in or create a free account to read this DrugPatentWatch article
